Skip directly to content


We know that transparency is essential to building and maintaining confidence in us and in our medicines. We want people to know, and understand, what we do and how we do it.

Our business is regulated by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry which has detailed requirements to ensure its member companies operate in a responsible, ethical and professional manner. The Code includes requirements for how we may work with healthcare professionals, healthcare organisations and patient organisations and in recent years it has introduced new requirements for greater transparency in these areas.

We strongly support the work the European Federation of Pharmaceutical Industries and Associations (EFPIA) and ABPI have done to move towards greater transparency across the pharmaceutical industry.


Working with healthcare professionals, healthcare organisations and patient organisations

Working with healthcare professionals (HCPs), healthcare organisations (HCOs) and patient organisations allows us to share knowledge and in turn, helps us to better prevent, treat and potentially cure diseases and improve the quality of people’s lives.

These working relationships mean we can use our knowledge to help healthcare professionals get the best out of our medicines, allow our scientists to monitor the impact of our treatments and to work in partnership with the NHS to deliver more effective and efficient care.

It is important the public feels confident our relationships are appropriate and beneficial. We're committed to transparency, and we hope that the healthcare professionals we work with feel the same. That is why Pfizer has taken the decision to only work in future with those who are happy to share information about our work together in the public domain.

Find out more about our work with healthcare professionals.


Financial support for healthcare professionals

We think HCPs should be appropriately paid for the time they invest and expertise they offer, but it is right to continually review how this works in practice.

Explore the data on our payments to UK healthcare professionals and healthcare organisations page. 


Financial or other support for healthcare organisations

Pfizer has close working relationships with healthcare organisations and there are occasions when we may offer financial or other types of support to the NHS and other organisations.

Find out more about how we're working with the NHS and other organisations.


Financial or other support for patient organisations

Pfizer exists to discover and develop medicines that save and improve the lives of patients. To succeed, we need to have a true understanding of what patients need so that we can do our best to achieve better outcomes for them. 

To do this, we work with patient experts who have expertise in a whole range of areas. At times, we provide financial aid such as charitable donations or sponsorships to support the organisation's work, paying for expert advice and providing non-financial benefits or 'benefits in kind' when we partner or collaborate on projects.

You can further explore our payments to patient organisations on our payments reports page.


Research and development

The UK has a long-standing reputation for research into medicine and advances in basic science mean we understand diseases better than we've ever done before.1 However, we know we can’t do it completely on our own. While our scientists are working hard to develop and discover medicines in our own laboratories, they also work with third parties from across life sciences.

As part of the ABPI's move towards greater transparency, pharmaceutical companies now share data on how much they have spent on conducting research and development activities in the UK. Find out more about what we spent last year.

You can also find information about our clinical trials at Every trial we run involving our compounds is registered and made public, including information about the purpose of each trial, the eligibility of patients to join the trial and the location of the study.

Find out more about how Pfizer runs and shares trial information.



  1. Last accessed May 2020.


      PP-PFE-GBR-2589 / May 2020